New data from Kryptoszene has revealed the cannabis industry is expected to see an increase in sales up to 374% until 2023. In only three years, a rise in demand for CBD-products will most likely result in a turnover of $23.7bn in the United States.
Medical cannabis, or cannabinoid-based products, continues to grow in popularity globally, driving the evolution of regulatory access frameworks; cancer patients and caregivers often rely on guidance from their physicians regarding cannabinoid-based treatments. But the majority of healthcare practitioners still feel unprepared and insufficiently informed to make reasonable, evidence-based recommendations about medical cannabis.
